EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancer
The Oncologist · 17.01.2026 · 31 (2)
DOI: 10.1093/oncolo/oyaf434 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Oncologist, online erschienen am 30.12.2025. Verfasst von Albert Jang und 29 weiteren Autor:innen. Beteiligte Einrichtung: Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44…. Hauptthemen laut MEDLINE: Phenylthiohydantoin, Antineoplastic Combined Chemotherapy Protocols, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Anitens are a family of oral N-terminal domain inhibitors of the androgen receptor (AR). In prostate cancer, they may help overcome AR resistance mechanisms at the ligand-binding domain, which is the binding site of approved androgen receptor pathway inhibitors like enzalutamide. Masofaniten (EPI-7386) is a next-generation aniten with promising activity and safety in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Methods
In this investigator-initiated, phase II, single-arm, single-institution trial, patients with treatment-naïve metastatic hormone-sensitive prostate cancer (mHSPC) were enrolled in a Simon 2-stage study design to receive the combination of masofaniten 600 mg BID and enzalutamide 160 mg daily with androgen deprivation therapy (ADT). The study was designed to enroll 35 patients (13 patients in stage 1, then 22 patients in stage 2). The trial would move to stage 2 if 9 or more subjects achieved a biochemical response at 6 months.
Results
Thirteen patients were screened and enrolled into stage 1. Five were African American, and 8 were Caucasian. The median age was 68 years (range 52-75) at time of enrollment. Median follow-up time was 9.9 months (range 7.7-13.6). Ten of 13 patients (77% with 95% CI: 50%-92%) achieved a PSA <0.2 ng/mL at 6 months, achieving the threshold to move on to stage 2. Only one patient had disease progression to mCRPC and died of disease at the time of data cutoff. Patients continued enzalutamide and ADT after trial closure.
Conclusion
The combination of masofaniten and enzalutamide for treatment-naïve mHSPC did show efficacy and had an acceptable safety profile. These results support further investigation of the dual AR blockade in mHSPC (ClinicalTrials.gov Identifier: NCT06312670).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States.
- Case Comprehensive Cancer Center, Cleveland, OH 44106, United States.
- ESSA Pharma Inc., South San Francisco, CA 94080, United States.
- Gilmour Academy, Cleveland, OH 44040, United States.
- University Hospitals Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, OH 44106, United States.
- Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44106, United States.
ORCID-Profile: Albert Jang, Victoria Delong, Jeffrey Y Zhong, Tanya Jindal, Abby L Grier, Amanda Nizam, Shilpa Gupta, Christopher E Wee, Pingfu Fu, Iris Y Sheng, Jason R Brown, Pedro C Barata
Zitieren
APA
Jang, A., Fowler, P., Helminiak, K., Kumar, H. L. S., Pasucal, J., Delong, V., Zhong, J. Y., Jindal, T., Grier, A. L., Patel, R. R., Hislop, M., Cesano, A., Villaluna, K., Younginger, B., Wolff, K., Richey, K., Bray, J., Garcia, H., Adamowicz, T., …, & Barata, P. C. (2026). EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancer. The Oncologist, 31(2). https://doi.org/10.1093/oncolo/oyaf434
Vancouver
Jang A, Fowler P, Helminiak K, Kumar HLS, Pasucal J, Delong V, et al. EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancer. The Oncologist. 2026;31(2). doi:10.1093/oncolo/oyaf434
BibTeX
@article{Jang2026,
author = {Jang, Albert and Fowler, Peggy and Helminiak, Kathryn and Kumar, Hamsa L S and Pasucal, Jeffrey and Delong, Victoria and Zhong, Jeffrey Y and Jindal, Tanya and Grier, Abby L and Patel, Rishi R and Hislop, Mary and Cesano, Alessandra and Villaluna, Karen and Younginger, Brett and Wolff, Kayla and Richey, Kara and Bray, Julie and Garcia, Hannah and Adamowicz, Timothy and Reese, Amy and Nizam, Amanda and Gupta, Shilpa and Wee, Christopher E and Margevicius, Seunghee and Fu, Pingfu and Mendiratta, Prateek and Sheng, Iris Y and Brown, Jason R and Garcia, Jorge A and Barata, Pedro C},
title = {EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancer},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {2},
doi = {10.1093/oncolo/oyaf434}
}
EUVIMED